Fragmin

Phase 3Small molecule

Pfizer

Fragmin is one of 39 small molecule programs targeting Pulmonary Embolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary EmbolismActive, not recruiting

Pulmonary EmbolismPreclinical

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Pulmonary Embolism

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

1 2

Xarelto

WWim Janssens

Approved

8 3

Pradaxa

Boehringer Ingelheim

Approved

1 4

Activase

Roche

Phase 3

7 5

Tnkase

Roche

Phase 3

2 6

Heparin Sodium

BBaxter Healthcare Corporation

Phase 3

2 7

Low-Molecular-Weight Heparin

Daiichi Sankyo

Phase 3

4 8

Lovenox

Sanofi

Phase 2

6 9

Recombinant Tissue Plasminogen Activator

BBoston Scientific Corporation

Phase 3

4 10

Direct Oral Anticoagulants

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Hypercoagulability

NCT06153394

Clinical

Trials by Indication[1]

Complication2 trials

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

Completed·JJonsson Comprehensive Cancer Center·Phase 3·NCT00006083

A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement

Unknown status·PPharmaDiall Ltd.·Phase 2·NCT05189002·240 enrolled

Treatment2 trials

Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00662831·276 enrolled

The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00765063·62 enrolled

Dialysis Patients1 trial

A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery

Completed·OOttawa Hospital Research Institute·Phase 2/3·NCT00260988·29 enrolled

Observational Study1 trial

An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®

Completed· Pfizer logo

Pfizer··NCT01046903·503 enrolled

Hypercoagulability1 trial

Prolonged Hypercoagulability Following Major Liver Resection for Malignancy

Not yet recruiting·WWestern University, Canada·Phase 3·NCT06153394·50 enrolled

3 more indications

MPR1 trial

Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)

Completed·HHamilton Health Sciences Corporation··NCT00138099·140 enrolled

Pulmonary Embolism1 trial

Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients

Completed· Pfizer logo

Pfizer··NCT00480636·102 enrolled

Hemodialysis1 trial

Use Of Fragmin In Hemodialysis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01879618·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Fragmin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fragmin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fragmin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Fragmin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Complication2 trials

Treatment2 trials

Dialysis Patients1 trial

Observational Study1 trial

Hypercoagulability1 trial

MPR1 trial

Pulmonary Embolism1 trial

Hemodialysis1 trial

References

Drug Info

Quick Facts

Related News